Two weeks ago, Vera Therapeutics beat Vertex to market as the first dual BAFF and APRIL inhibitor approved for IgA nephropathy. We flagged it as a race worth watching. It just became a three way contest. Novartis won full FDA approval for Fabhalta to slow kidney function decline in IgAN, converting an earlier accelerated approval into a full label. That puts three drugs in play almost simultaneously in a disease that not long ago had almost nothing.
Vera’s Trutakna is approved. Novartis’s Fabhalta now has full approval. Vertex’s povetacicept is under review with a November 30 decision date. Three drugs, overlapping mechanisms, one disease, and a commercial fight that will be decided by prescriber habits, payer coverage, and whatever data separates them. For patients with a progressive kidney disease that damages the kidneys over years and leads to dialysis or transplant, three options in the span of months is the kind of breakthrough that does not get enough attention because it is happening in nephrology rather than oncology.
Meanwhile, J&J opened Q2 earnings season soft, with oncology sales missing expectations and shares slipping. GSK killed camlipixant after mixed Phase 3 data in chronic cough, its second abandoned late stage program in a month. The China deadline passed Friday without a public reveal, exactly as expected. And flu season prep started, with CSL Seqirus shipping the first vaccines of the 2026/27 U.S. season.
Novartis Fabhalta Gets Full Approval, and IgA Nephropathy Becomes a Real Market
What Happened: The FDA granted full approval to Novartis’s Fabhalta (iptacopan) to slow kidney function decline in adults with primary IgA nephropathy at risk of progression, converting an earlier accelerated approval.
Three Drugs, Three Mechanisms, One Disease That Had Nothing
IgA nephropathy is a chronic kidney disease in which the immune system produces abnormal immunoglobulin A antibodies that deposit in the kidneys, causing inflammation and progressive damage. Over years, the disease can destroy enough kidney function to require dialysis or transplant. For decades, the treatment was limited to blood pressure management, immunosuppression, and supportive care. No therapies specifically targeted the disease mechanism.
Now three drugs have arrived in rapid succession, each attacking the immune pathology through a different approach:
Vera’s Trutakna (atacicept): A dual BAFF and APRIL inhibitor that blocks two proteins involved in the abnormal antibody production driving IgAN. Approved in early July. First mover advantage. Once weekly auto injector.
Novartis’s Fabhalta (iptacopan): A complement inhibitor that blocks complement factor B, targeting the inflammatory cascade downstream of the antibody deposition. Full approval today. Oral formulation, which is a meaningful convenience advantage over injection.
Vertex’s povetacicept: Also targets the BAFF and APRIL pathways, similar to Trutakna. November 30 PDUFA date. Would enter the market last but with Vertex’s substantial commercial resources and clinical development expertise behind it.
How the Competition Plays Out
The mechanism differences matter for how physicians and payers evaluate the options. Fabhalta hits the complement system, a different biological node than the BAFF and APRIL axis that both Trutakna and povetacicept target. That gives Novartis a cleaner differentiation story—its drug works through a genuinely distinct mechanism. Vera and Vertex, both targeting BAFF and APRIL, will compete more directly against each other, where the distinctions come down to dosing convenience, safety profiles, and the depth of proteinuria and kidney function improvement each drug demonstrates.
Fabhalta’s oral formulation is a competitive advantage in a chronic disease where patients take their medication daily for years. An oral pill versus a weekly injection is a meaningful practical difference for a patient managing a lifelong kidney condition alongside other health challenges. Novartis also brings the commercial scale of one of the largest pharmaceutical companies in the world—deeper physician relationships, broader payer coverage networks, and the resources to run the post marketing studies that build long term confidence in a new drug.
Vera has the advantage of being first to market in the BAFF and APRIL space. Nephrologists who start patients on Trutakna and see positive results have limited reason to switch when a similar drug from Vertex arrives months later. First movers in specialty disease markets build durable prescriber relationships that latecomers have to work hard to break.
The November 30 Vertex decision is the next catalyst. If povetacicept shows a differentiated profile—perhaps deeper proteinuria reduction, a cleaner safety signal, or a more convenient dosing schedule—it can still capture meaningful share despite entering last. Vertex has shown with its cystic fibrosis franchise that commercial execution can overcome a later market entry when the product is genuinely good.
For IgAN patients, the takeaway is straightforward and positive. A disease that had almost nothing a year ago now has three drugs from three major companies, attacking the problem through at least two distinct biological pathways. More options mean more patients can find a treatment that works for them. That is what it looks like when science finally cracks a stubborn disease.
Our Pro brief maps how the Vera, Novartis, and Vertex fight gets decided and what the November 30 Vertex decision means for the competitive landscape. [Details below.]
J&J Opened Earnings Season Soft, and Now the Numbers Have to Back Up the Mood
What Happened: J&J kicked off Q2 earnings with shares slipping as oncology sales missed expectations.
Sentiment Is Not Performance
The pharmaceutical industry enters earnings season in its best spirits in years. Record M&A ($134 billion plus across 33 deals over $1 billion). Thirteen IPOs raising $4.1 billion. A friendlier FDA under acting leadership. PwC declaring the ecosystem “back to full health.” The mood at BIO described as the most optimistic in years. Everything points up.
J&J’s Q2 is a reminder that sentiment and execution are different things. Oncology is the most competitive therapeutic area in the industry. Every major pharmaceutical company is investing heavily in it. When a company the size of J&J misses in oncology, it tells you that even in a healthy market, individual franchises face competitive pressure that no amount of favorable industry conditions can override.
What to Watch on the Calls
The big pharmas report over the next two weeks, and we are listening for three things.
Dealmaking signals. With the M&A wave running at historic pace and multiple major deals closing in Q3, every large cap will be asked what they plan to buy next. How aggressively management signals continued acquisitions—versus capital return through buybacks and dividends—sets expectations for whether the second half deal pace holds. Lilly at fifteen deals, AbbVie at multiple billion dollar acquisitions, and Vertex at $10 billion for Crinetics are all setting a pace that peers will be asked to match.
China exposure. With the congressional probe fresh and the responses just submitted, analysts will press on China strategy. Watch for careful reassurance and for any hint that a company is reconsidering its China licensing pipeline. The gap between what executives say on earnings calls and what their companies actually do—as AstraZeneca demonstrated by signing five deals during the probe—is itself the signal worth tracking.
GLP 1 trajectory. For Lilly and Novo specifically, the questions will be about supply, Medicare Bridge enrollment since the July 1 launch, retatrutide’s two pivotal wins and filing timeline, and the competitive dynamics between Foundayo (oral), Zepbound (injectable), and Wegovy in both the U.S. and Europe after the oral EU approval. These franchises are carrying an enormous amount of the market’s growth expectations, and the Q2 prints will either validate that weight or raise questions about it.
GSK Killed Camlipixant After Mixed Phase 3 Data in Chronic Cough
What Happened: GSK ended development of camlipixant after mixed Phase 3 results from its CALM 1 and CALM 2 trials in refractory chronic cough.
Two Abandoned Programs in a Month
Camlipixant is a P2X3 receptor antagonist that analysts had viewed as a potential blockbuster and a key pipeline catalyst. Refractory chronic cough is a stubborn, under treated condition where patients have coughed for months or years without relief from existing treatments. The unmet need is real. The market opportunity was significant. And the data came in mixed.
GSK cutting it fits the pattern we have tracked under Luke Miels. Weeks ago, the company walked away from its $2.2 billion Alector neurodegeneration partnership after both drugs failed. Now it has killed a potential blockbuster in chronic cough after the Phase 3 results disappointed. Two abandoned late stage programs in a month.
The discipline is defensible. The industry is full of examples of companies that pushed marginal assets into expensive Phase 3 trials or launches and paid dearly for it. Cutting fast when the data disappoint preserves capital for better bets. Under Miels, GSK has shown consistent willingness to make hard calls, and that discipline is part of what has made the company’s capital allocation among the most respected in the sector.
But discipline only works if the remaining pipeline delivers. Each abandoned program increases the weight on what GSK is keeping. The $10.6 billion Nuvalent acquisition (zidesamtinib for ROS1 lung cancer, neladalkib for ALK lung cancer) now carries even more of the company’s growth expectations. When you cut fast, you need a deep bench behind the cuts. GSK’s bench is getting thinner, and the margin for further disappointment is shrinking. The Nuvalent drugs, under FDA review with PDUFAs expected this year, are increasingly central to the GSK growth story.
The China Deadline Passed Quietly, and 100 Plus Deals Tell the Story
Friday’s deadline for Merck, AbbVie, Lilly, Pfizer, and BMS to respond to the House Select Committee on China came and went without a public reveal, exactly as we said it would. The responses went to the committee and will surface in fragments over the coming weeks as the committee decides what to disclose and when.
What is visible is the deal flow, and it continues to tell its own story. BioPharma Dive reported that Chinese drugmakers have now formed more than 100 licensing pacts with U.S. companies. One hundred deals. That is not a trend being tested. That is an operating model the entire industry has adopted.
The through line we tracked for a month holds: the political pressure is real, the responses will surface gradually, and the industry keeps signing. AstraZeneca alone signed five China deals since the start of 2025, including a $600 million upfront for Dizal’s approved lung cancer drug three days before the deadline. The five named companies submitted their letters and will move on. The fight that matters remains the Biotech Investment National Security Act, which would route China licensing deals through Treasury review and still awaits a committee vote. That is the story to watch through the fall—not the deadline that just passed, but the legislation that could actually change the rules.
Flu Season Prep Starts Early, Targeting Last Year’s Problem Strain
CSL Seqirus began shipping influenza vaccines for the 2026/27 U.S. season, targeting the H3N2 subclade K strain that drove last year’s historic surge. Early shipping helps healthcare providers prepare, and the strain match matters. Last season’s severity was driven partly by how the circulating virus diverged from the vaccine strain, reducing effectiveness and contributing to a particularly bad flu year.
The timing also connects to the Moderna mRNA flu vaccine, which cleared the FDA advisory committee in June and is awaiting a final approval decision. If approved, the mRNA flu vaccine would enter its first commercial season competing against the established egg based and cell based products from Sanofi, Seqirus, and GSK. The mRNA platform’s faster manufacturing timeline—weeks rather than months—could allow better strain matching than traditional approaches. CSL Seqirus shipping early with a targeted strain is the incumbent’s answer: move fast, match well, and let production scale do the work.
Quick Hits
Lilly’s AtaiBeckley terms firmed up. The psychedelics deal is $2.8 billion upfront and up to $3.8 billion total. Reporting tied the accelerating research environment partly to a Trump executive order on psychedelics. It is roughly Lilly’s fifteenth deal of the year.
The FDA keeps walking back Makary. Acting Commissioner Kyle Diamantas ended the practice of making policy through medical journal articles, another step in the reversal pattern we have tracked since the spring. The FDA under acting leadership continues to take a less confrontational posture than it did during the Makary and Prasad era.
Danaher is buying again. Its Leica Biosystems unit agreed to acquire Statlab Medical Products, strengthening its diagnostics and pathology portfolio. More evidence of the med tech consolidation we flagged when med tech M&A hit $75.73 billion in the first half.
Takeda posted Phase 3 data for zasocitinib, its next generation oral TYK2 inhibitor. The drug advances Takeda’s inflammatory disease pipeline under new CEO Julie Kim, who was formally appointed in June and inherited a transformation program including 4,500 global job cuts.
Strategic Themes
1. IgA Nephropathy Going from Nothing to Three Drugs Is What Scientific Breakthrough Looks Like in Real Time
A disease that had no approved targeted therapy a year ago now has three drugs from three major companies, attacking the problem through at least two distinct biological pathways. The speed of convergence—Vera in early July, Novartis today, Vertex by November—gives patients options that did not exist twelve months ago. For the industry, IgAN is the latest example of a pattern we have tracked all year: when the science cracks a disease, the commercial competition follows immediately. The window between breakthrough and competition is getting shorter.
2. J&J’s Soft Open Is a Reminder That Sentiment and Execution Are Different Things
The industry is in its best mood in years. The M&A wave is historic. The IPO window is wide open. But Q2 earnings are where the rhetoric meets the numbers, and J&J’s oncology miss shows that competitive pressure does not take a quarter off just because the macro environment is favorable. The calls over the next two weeks will test whether the optimism is earned across the sector or concentrated in the companies that are actually executing.
3. GSK Cutting Fast Is Disciplined, But the Bench Is Getting Thinner
Camlipixant killed after mixed data. Alector terminated after both drugs failed. Two abandoned late stage programs in a month. The discipline is right—killing failing programs early preserves capital. But each cut puts more weight on the remaining pipeline, and the Nuvalent acquisition now carries an outsized share of GSK’s growth expectations. The zidesamtinib and neladalkib PDUFAs expected this year are no longer just pipeline catalysts. They are the load bearing assets of the entire growth story.
4. One Hundred China Deals Is an Operating Model, Not a Trend
Chinese drugmakers have formed more than 100 licensing pacts with U.S. companies. The congressional probe, the July 17 deadline, and the Biotech Investment National Security Act are all real. But 100 deals represent a structural integration of Chinese innovation into the Western pharmaceutical pipeline that cannot be unwound by letters and hearings. The question is not whether the industry stays in China. It is whether the political cost of staying rises high enough to change the economics at the margin.
Frequently Asked Questions
What is the IgA nephropathy three way race?
Vera’s Trutakna (dual BAFF/APRIL inhibitor, approved July), Novartis’s Fabhalta (oral complement inhibitor, full approval today), and Vertex’s povetacicept (BAFF/APRIL, November 30 PDUFA). Three drugs, overlapping mechanisms, a disease that had almost nothing a year ago.
How did J&J’s earnings look?
Shares slipped as oncology sales missed expectations, opening Q2 earnings season with a cautionary note. The big pharmas report over the next two weeks. We are watching for dealmaking signals, China exposure comments, and GLP 1 trajectory.
Why did GSK kill camlipixant?
Mixed Phase 3 results in refractory chronic cough (CALM 1 and CALM 2 trials). It is the second abandoned late stage program in a month, after the Alector neurodegeneration walk. The Nuvalent acquisition now carries more weight in GSK’s growth story.
What happened with the China deadline?
Responses went to the committee Friday, no public reveal. Chinese drugmakers have formed 100 plus licensing pacts with U.S. companies. The deal flow has not slowed. The Biotech Investment National Security Act, which would add Treasury review to China deals, is the legislation to watch through the fall.
When is the Vertex IgAN decision?
November 30 PDUFA date for povetacicept. If approved, Vertex enters the IgAN market as the third player behind Vera and Novartis.
What were the Lilly AtaiBeckley final terms?
$2.8 billion upfront and up to $3.8 billion total. Roughly Lilly’s fifteenth deal of 2026, entering psychedelic based mental health treatment.
BioMed Nexus Pro — What Institutional Subscribers Are Reading Today
IgA Nephropathy’s Three Way Race. We map how the Vera, Novartis, and Vertex fight gets decided—mechanism differentiation, oral versus injectable format, first mover dynamics, and what the November 30 Vertex PDUFA means for the competitive landscape.
Earnings Season Opens Soft. We lay out the three questions that matter on the big pharma calls (dealmaking, China, GLP 1), assess why J&J’s oncology miss is a warning worth heeding, and identify which companies face the most scrutiny this quarter.
GSK Keeps Cutting. We evaluate whether the fast cutting is disciplined capital allocation or a pipeline running thin, assess how much weight the Nuvalent assets now carry, and model the consequences if either zidesamtinib or neladalkib disappoints.
Plus: China 100 deal landscape, CSL flu vaccine strain match, Lilly AtaiBeckley final terms, Takeda zasocitinib data, Danaher diagnostics deal, Section 232 countdown (11 days), and the full H2 catalyst calendar.
About BioMed Nexus
BioMed Nexus delivers institutional grade intelligence to biotech and pharma executives, investors, and clinicians. Our daily briefings and deep dive analyses cut through the noise to deliver the strategic insights that drive better decision making in the life sciences.
Subscribe to receive daily updates and gain access to BioMed Nexus Pro institutional intelligence briefs.
